-
Well-known pharmaceutical company announced the abolition of employees
Time of Update: 2021-04-19
, it is no exception. In China, it is mainly manifested as changes in the sales team with volume procurement products: Recently, many foreign pharmaceutical companies have announced staff adjustments and layoffs, including adjustments
-
The results of the fourth batch of national procurement, 4 provinces clarify the landing time
Time of Update: 2021-04-19
> On March 26, the Henan Medical Insurance Bureau issued the "Notice on Doing a Good Job in the Implementation of the Fourth Batch of National Organizations for the Implementation of Centralized
-
Sell 16.8 billion to a new high!
Time of Update: 2021-04-19
chain, accelerate the production of new standards for varieties, optimize the preparation process, continue to expand the construction of medicinal planting bases, and ensure the quality of medicinal materials And the quality is stable, forming
-
The most comprehensive analysis of formula particles: policy, market, competing products, marketing...
Time of Update: 2021-04-19
issued the "Announcement on the Pilot Uniform Standards for the Varieties of Formula Granules". The implementation of this policy will improve the quality standard construction of TCM formula granules, increase the barriers to new entrants
-
The results of the fourth batch of national selection, six provinces have clarified the implementation time
Time of Update: 2021-04-19
products announced by the National Procurement and the results of the selection from April 27, 2021. At the same time, Jiangsu Province requires the fourth batch of nationally-sourced drugs
-
The national pharmacy renovation begins!
Time of Update: 2021-04-19
detection and elimination of signs and tendencies; the second is the full implementation of governance responsibilities, and the implementation of all responsibilities to people; the third is management The level has been comprehensively improved
-
The National Health and Medical Commission's Medical Management Bureau issued the "Long-term Prescription Management Standards"
Time of Update: 2021-04-19
Chapter 5 Long-term prescription drug management Article 26 Primary medical and health institutions shall include the long-term prescription information issued by the institution in the patient's health file, and record the patient's diagnosis and treatment and medication records in detail.
-
Chinese biopharmaceuticals are trapped in a prisoner’s dilemma: the original innovative drugs have little investment and get together with innovative drugs
Time of Update: 2021-04-19
Therefore, the truly original and innovative drugs needed by patients and the market are in a prisoner's dilemma where no investment can be obtained.
-
None of the five global top 10 generic drug companies in India are from China!
Time of Update: 2021-04-19
Allergan's generic drug business acquired by Teva was renamed through continuous mergers and acquisitions by Watson Pharmaceuticals, the third largest generic drug company in the United States.
-
Pfizer announces Phase 3 clinical results of abrocitinib, a new-generation oral JAK1 inhibitor
Time of Update: 2021-04-19
(100mg, 200mg, once a day, orally), positive control drug dupilumab (300mg, baseline 600mg loading dose, once every 2 weeks, subcutaneous injection), placebo efficacy and safety, all patients received topical therapy.
-
Detailed analysis of TOP20 global pharmaceutical companies by revenue in 2020!
Time of Update: 2021-04-19
S. dollars, and it is expected that COVID-19 vaccine sales this year will reach approximately 15 billion U.
-
The domestic pharmaceutical packaging material industry, which is constantly catching up and upgrading from bottle cap to bottle body, has a promising future
Time of Update: 2021-04-19
Previously, according to information disclosed by the China Vaccine Industry Association, there are currently more than 60 domestic manufacturers of relevant pharmaceutical packaging materials.
-
The Central Commission for Discipline Inspection issued a document to strictly investigate medical corruption, hospital leaders were investigated
Time of Update: 2021-04-19
days, using self-inspection combined with on-site inspections, starting in November 2019, and completing this round of inspections before the end of June 2022—that is, Inspections in large hospitals are still in progress. </div
-
Recall of 4 batches of injections caused by solution crystallization
Time of Update: 2021-04-19
Injection produces crystalsInjection produces crystalsRecall announcementRecall announcementAfter receiving several complaints about injection crystallization, Zydus Pharmaceutical Company in the United States voluntarily recalled four batches of acyclovir sodium injection 50 mg/mL, with two packaging specifications of 10 mL and 20 mL.
-
Bayer's pulmonary hypertension drug Adempas reaches its primary endpoint in Phase IV clinical trial
Time of Update: 2021-04-19
Compile Ke KeOn March 29, Bayer announced the publication of Phase IV clinical data of the pulmonary hypertension drug Adempas (riociguat) in The Lancet Respiratory Medicine.
-
Hengrui Pharmaceuticals ERK Inhibitor Approved for Clinical
Time of Update: 2021-04-19
On March 26, the CDE official website showed that Hengrui's application for clinical trial of extracellular regulatory protein kinase (ERK) inhibitors has been approved by the State Food and Drug Administration by default.
-
Hengrui Medicine SHR8008 capsules and HRS2543 tablets were approved for clinical trials
Time of Update: 2021-04-19
After inquiries, at present, fluconazole, itraconazole, voriconazole and isaconazole and other similar products of SHR8008 have been approved for marketing at home and abroad.
-
Johnson & Johnson's S1P1 regulator Ponvory (ponesimod) is about to be approved in the EU
Time of Update: 2021-04-19
the annual recurrence rate (the annual recurrence rate is reduced by nearly One-third), and more than 10 years of cumulative clinical research data have proven its effectiveness and safety. >Aubagio is an oral drug
-
Simcere Pharmaceuticals obtains exclusive rights to anti-cancer drug paxalisib in Greater China
Time of Update: 2021-04-19
childhood disease identification and orphan drug qualification. >According to the agreement, Simcere will be responsible for the development, registration and commercialization of paxalisib in the Greater China
-
Health yuan hits new inhaler medicine again!
Time of Update: 2021-04-19
Figure 1: Healthyuan’s application status of aclidinium bromide inhalation powderSource: CDE official websiteTable 1: The status of key inhalant products declared by Joincare and its subsidiaries earlierSource: Meinenet MED2.
